Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer
-
M. Majem [1] ; J. Hernández Hernández [2] ; F. Hernando Trancho [3] ; N. Rodríguez de Dios [4] ; A. Sotoca [5] ; J. C. Trujillo Reyes [1] ; I. Vollmer [8] ; R. Delgado Bolton [6] ; M. Provencio [7]
-
[1] Hospital de la Santa Creu i Sant Pau
Hospital de la Santa Creu i Sant Pau
Barcelona, España
-
[2] Complejo Asistencial de Ávila
Complejo Asistencial de Ávila
Ávila, España
-
[3] Hospital Clínico San Carlos de Madrid
Hospital Clínico San Carlos de Madrid
Madrid, España
-
[4] Hospital del Mar
Hospital del Mar
Barcelona, España
-
[5] Hospital Ruber Internacional
Hospital Ruber Internacional
Madrid, España
-
[6] Hospital San Pedro
Hospital San Pedro
Logroño, España
-
[7] Hospital Universitario Puerta de Hierro
Hospital Universitario Puerta de Hierro
Madrid, España
-
[8] Hospital Clínic, Barcelona
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 1, 2020, págs. 21-36
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Stage III non-small cell lung cancer (NSCLC) is a very heterogeneous disease that encompasses patients with resected, potentially resectable and unresectable tumours. To improve the prognostic capacity of the TNM classification, it has been agreed to divide stage III into sub-stages IIIA, IIIB and IIIC that have very different 5-year survival rates (36, 26 and 13%, respectively). Currently, it is considered that both staging and optimal treatment of stage III NSCLC requires the joint work of a multidisciplinary team of expert physicians within the tumour committee. To improve the care of patients with stage III NSCLC, different scientific societies involved in the diagnosis and treatment of this disease have agreed to issue a series of recommendations that can contribute to homogenise the management of this disease, and ultimately to improve patient care
